to-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases

04-Nov-2009 - Netherlands

to-BBB, the Dutch brain drug delivery company, has entered into a research collaboration with Genzyme Corporation to evaluate to-BBB’s proprietary G-Technology™ to safely enhance delivery of biologics for neurodegenerative diseases.

The disease modifying properties of biological drugs, like peptides, enzymes and antibodies have become well established in the last decades as important medicines. The treatment of brain diseases with these modern treatments is unfortunately hampered by the inability of such drugs to easily pass the blood-brain barrier (BBB).

to-BBB’s G-Technology is designed to transport different classes of drugs across the blood-brain barrier by formulating these drugs into proprietary glutathione coated liposomes. The company has shown proof of concept in different disease models and Genzyme will now evaluate the technology in its disease models.

Geoff McDonough, senior vice president at Genzyme says, "This collaboration will explore an essential component of our work to deliver therapies to the brain, and could further our commitment to patients with neuronopathic disease."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous